🚀 VC round data is live in beta, check it out!
Fresenius Valuation Multiples
Discover revenue and EBITDA valuation multiples for Fresenius and similar public comparables like Mindray, Steris, Dr. Sulaiman Al Habib, Alcon and more.
Fresenius Overview
About Fresenius
Fresenius SE is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
Founded
1912
HQ
Employees
179.9K
Website
Financials (LTM)
EV
$45B
Fresenius Financials
Fresenius reported last 12-month revenue of $27B and EBITDA of $4B.
In the same LTM period, Fresenius generated $7B in gross profit, $4B in EBITDA, and $2B in net income.
Revenue (LTM)
Fresenius P&L
In the most recent fiscal year, Fresenius reported revenue of $27B and EBITDA of $4B.
Fresenius expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $27B | XXX | $27B | XXX | XXX | XXX |
| Gross Profit | $7B | XXX | $7B | XXX | XXX | XXX |
| Gross Margin | 26% | XXX | 25% | XXX | XXX | XXX |
| EBITDA | $4B | XXX | $4B | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| EBIT Margin | 12% | XXX | 12% | XXX | XXX | XXX |
| Net Profit | $2B | XXX | $2B | XXX | XXX | XXX |
| Net Margin | 8% | XXX | 7% | XXX | XXX | XXX |
| Net Debt | — | — | $11B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Fresenius Stock Performance
Fresenius has current market cap of $33B, and enterprise value of $45B.
Market Cap Evolution
Fresenius' stock price is $58.13.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $45B | $33B | -0.5% | XXX | XXX | XXX | $3.39 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialFresenius Valuation Multiples
Fresenius trades at 1.7x EV/Revenue multiple, and 10.4x EV/EBITDA.
EV / Revenue (LTM)
Fresenius Financial Valuation Multiples
As of March 27, 2026, Fresenius has market cap of $33B and EV of $45B.
Equity research analysts estimate Fresenius' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Fresenius has a P/E ratio of 16.4x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $33B | XXX | $33B | XXX | XXX | XXX |
| EV (current) | $45B | XXX | $45B | XXX | XXX | XXX |
| EV/Revenue | 1.7x | XXX | 1.7x | XXX | XXX | XXX |
| EV/EBITDA | 10.4x | XXX | 10.5x | XXX | XXX | XXX |
| EV/EBIT | 14.7x | XXX | 14.9x | XXX | XXX | XXX |
| EV/Gross Profit | 6.5x | XXX | 6.9x | XXX | XXX | XXX |
| P/E | 16.4x | XXX | 17.1x | XXX | XXX | XXX |
| EV/FCF | 22.8x | XXX | 22.5x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Fresenius Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Fresenius Margins & Growth Rates
Fresenius' revenue in the last 12 month grew by 3%.
Fresenius' revenue per employee in the last FY averaged $0.1M.
Fresenius' rule of 40 is 20% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Fresenius' rule of X is 25% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Fresenius Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | 16% | XXX | XXX | XXX |
| EBITDA Growth | 5% | XXX | 4% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 20% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 25% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 0% | XXX | 3% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 13% | XXX | 10% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 3% | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 15% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Fresenius Public Comps
See public comps and valuation multiples for other Hospitals & Clinics and Medical Supplies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Mindray | XXX | XXX | XXX | XXX | XXX | XXX |
| Steris | XXX | XXX | XXX | XXX | XXX | XXX |
| Dr. Sulaiman Al Habib | XXX | XXX | XXX | XXX | XXX | XXX |
| Alcon | XXX | XXX | XXX | XXX | XXX | XXX |
| Tenet Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Fresenius M&A Activity
Fresenius acquired XXX companies to date.
Last acquisition by Fresenius was on XXXXXXXX, XXXXX. Fresenius acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Fresenius
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialFresenius Investment Activity
Fresenius invested in XXX companies to date.
Fresenius made its latest investment on XXXXXXXX, XXXXX. Fresenius invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Fresenius
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Fresenius
| When was Fresenius founded? | Fresenius was founded in 1912. |
| Where is Fresenius headquartered? | Fresenius is headquartered in Germany. |
| How many employees does Fresenius have? | As of today, Fresenius has over 179K employees. |
| Is Fresenius publicly listed? | Yes, Fresenius is a public company listed on Frankfurt Stock Exchange. |
| What is the stock symbol of Fresenius? | Fresenius trades under FRE ticker. |
| When did Fresenius go public? | Fresenius went public in 1992. |
| Who are competitors of Fresenius? | Fresenius main competitors are Mindray, Steris, Dr. Sulaiman Al Habib, Alcon. |
| What is the current market cap of Fresenius? | Fresenius' current market cap is $33B. |
| What is the current revenue of Fresenius? | Fresenius' last 12 months revenue is $27B. |
| What is the current revenue growth of Fresenius? | Fresenius revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of Fresenius? | Current revenue multiple of Fresenius is 1.7x. |
| Is Fresenius profitable? | Yes, Fresenius is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Fresenius? | Fresenius' last 12 months EBITDA is $4B. |
| What is Fresenius' EBITDA margin? | Fresenius' last 12 months EBITDA margin is 16%. |
| What is the current EV/EBITDA multiple of Fresenius? | Current EBITDA multiple of Fresenius is 10.4x. |
| What is the current FCF of Fresenius? | Fresenius' last 12 months FCF is $2B. |
| What is Fresenius' FCF margin? | Fresenius' last 12 months FCF margin is 8%. |
| What is the current EV/FCF multiple of Fresenius? | Current FCF multiple of Fresenius is 22.8x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.